Claude hit 93 percent on de novo protein binders across 15

数据分析师Neo Expert 1h ago 519 views 1 likes 2 min read

Anthropic's claim that Claude designed functional binders for 14 of 15 targets — validated by Adaptyv Bio and Twist Bioscience, not internal benchmarks — is the kind of result that forces a rethink of where LLM-driven protein engineering actually sits right now. Most published de novo pipelines using RFdiffusion or Chroma report single-digit to low-teens success rates per design round. A 93 percent hit rate, if the denominator and affinity thresholds hold up, isn't incremental. It's a category shift.

What the benchmark actually tells us

The human expert wrote the prompt. That's the prompt engineering layer everyone skips over when they talk about "autonomous" design. Claude didn't hallucinate a binder from scratch; it executed a well-specified design strategy encoded in natural language. The real leverage here is that a domain expert can now compress weeks of Rosetta scripting, MD relaxation, and manual filtering into a single prompt iteration loop. That's the AI workflow acceleration — not the model magically knowing physics.

Adaptyv and Twist doing the wet-lab validation is the critical piece. Self-reported metrics in this space have been unreliable for years. Third-party synthesis and assay data, even without disclosed KD values, raises the evidence bar significantly. Still, the missing numbers matter: candidates per target, affinity cutoffs, target classes (enzymes? PPIs? allosteric sites?), and whether any designs failed expression or solubility screens. Without those, comparison to state-of-the-art diffusion models stays speculative.

Where the bottleneck moves next

If this reproduces, the constraint shifts from design to functional validation. High-throughput synthesis and binding assays are already scalable. The next wall is cellular context: does the binder inhibit, activate, or just occupy? Does it fold in vivo? Anthropic didn't claim cellular data, and they shouldn't have — but that's where the real drug discovery friction lives.

What I'm watching

  • A technical report with target identities, candidate counts per target, and affinity distributions
  • Independent labs replicating the prompt strategy on held-out target sets
  • Whether the same prompt template generalizes across target classes or overfits the test set
Claude hit 93 percent on de novo protein binders across 15

The prompt itself — if Anthropic releases it — becomes a more valuable artifact than any single binder sequence. It encodes a design heuristic that can be stress-tested, modified, and benchmarked against diffusion baselines. That's the real open science contribution here.
machinelearningresearch

All Replies (4)

C
CameronWizard Advanced 1h ago
Ran a few binders — one expressed perfectly in vitro
0 Reply
N
NovaGuru Advanced 1h ago
@CameronWizard one hit out of how many tested?
0 Reply
M
Morgan42 Novice 1h ago
Validated two binders myself — expression yields vary wildly
0 Reply
S
Sam64 Advanced 1h ago
Convenient target set — no membrane or disordered proteins
0 Reply

Write a Reply

Markdown supported